Sorry...!!! You are not eligible for this website
AF Peptides logo
Age Verification

You must be 21+ years old to visit our website. Select your preference below.

Important Disclaimer: This product is sold strictly for research and laboratory use only and is not intended for human or animal consumption, medical, diagnostic, or therapeutic purposes.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

SLU-PP-332 1mg Tablets

$199.99

SKU: AFP-SLUPP-1MG-T100

60 in stock

View lab report (COA)

Research Highlights

SLU-PP-332 is an experimental small molecule most commonly studied in laboratory research involving:

  • Estrogen-related receptor alpha, beta, and gamma signaling
  • Mitochondrial respiration and oxidative metabolism
  • Skeletal-muscle fiber programming
  • Exercise-responsive gene-expression pathways
  • Energy expenditure and metabolic-homeostasis models

About SLU-PP-332

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors ERRalpha, ERRbeta, and ERRgamma, with substantial experimental activity associated with ERRalpha. Despite their name, estrogen-related receptors do not bind estrogen. They are orphan nuclear receptors that help regulate mitochondrial function, oxidative metabolism, energy use, and the expression of genes involved in cellular adaptation.

In cultured skeletal-muscle cells, researchers have reported changes in mitochondrial respiration and the expression of oxidative-metabolism genes. Mouse studies have examined shifts toward more oxidative muscle-fiber characteristics, exercise-responsive genetic programs, energy expenditure, and metabolic markers. These findings led researchers to describe SLU-PP-332 as an experimental “exercise-mimetic” research tool; that term refers only to selected molecular and metabolic patterns observed in controlled preclinical models and does not mean the compound reproduces exercise or its full effects.

Evidence for SLU-PP-332 remains preclinical, with no established human safety, effectiveness, pharmacokinetics, or appropriate exposure level. Published research also reports that the original SLU-PP-332 compound lacks oral bioavailability. Providing the material in a tablet format does not establish oral absorption, clinical suitability, or a direction for consumption.

Product Details

  • Compound: SLU-PP-332
  • Amount: 1mg nominal research material per tablet
  • Compound class: Synthetic pan-ERR agonist; not a peptide
  • Primary research targets: ERRalpha, ERRbeta, and ERRgamma
  • Format: Tableted research material
  • Quantity: Confirm the current tablet count against the product label and batch documentation
  • Testing: Product-specific certificate of analysis available

Important Notice

IMPORTANT DISCLAIMER — FOR LABORATORY RESEARCH USE ONLY

This product is intended exclusively for laboratory research purposes. It is not intended for human or animal consumption or for human or veterinary use, administration, ingestion, injection, inhalation, implantation, topical application, compounding, medical use, diagnostic use, or therapeutic use.

This product is not approved by the U.S. Food and Drug Administration for human or veterinary use. It is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. AF Peptides makes no representation regarding its safety, effectiveness, or suitability for any clinical, therapeutic, diagnostic, personal, or household application.